abiraterone acetate (Zytiga)
Jump to navigation
Jump to search
Indications
- treatment of prostate cancer*
* initial FDA approval for prostate cancer that has progressed after treatment with docetaxel[4]
* metastatic prostate cancer with no or mild symptoms after failed androgen deprivation therapy (NICE)
Dosage
- 1000 mg QD
- in combination with prednisone or prednisolone before chemotherapy (NICE)
- in combination with prednisone or prednisolone & androgen deprivation therapy[6]
Adverse effects
- inhibits cortisol synthesis
- syndrome of secondary mineralocorticoid excess
Mechanism of action
- inhibits CYP17A1
- inhibits corticosteroid synthesis
- inhibits extragonadal androgen synthesis (adrenal DHEA synthesis)
More general terms
References
- ↑ Attard G et al Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009 Aug 10; 27:3742. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19470933
- ↑ Reid AHM et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010 Feb 16; [e-pub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20159823 <Internet> http://dx.doi.org/10.1200/JCO.2009.24.6819
- ↑ de Bono JS et al Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21612468
Antonarakis ES and Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011 May 26; 364:2055. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21612475 - ↑ 4.0 4.1 4.2 FDA News Release: Dec. 10, 2012 FDA expands Zytiga's use for late-stage prostate cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm331492.htm
- ↑ Ryan CJ et al Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy N Engl J Med. December 10, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23228172 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1209096
- ↑ 6.0 6.1 James ND, de Bono JS, Spears MR et al Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Eng J Med. June 3, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28578639 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1702900
Fizazi K, Tran N, Fein L et al Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Eng J Med. June 4, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28578607 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1704174 - ↑ Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019